✦ LIBER ✦

Rituximab and B-Cell Return in ANCA-Associated Vasculitis

✍ Scribed by Wilde, Benjamin; Witzke, Oliver; Cohen Tervaert, Jan Willem

Book ID: 124144633
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 74 KB
Volume: 63
Category: Article
ISSN: 0272-6386
DOI: 10.1053/j.ajkd.2013.11.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

In Reply to ‘Rituximab and B-Cell Return

In Reply to ‘Rituximab and B-Cell Return in ANCA-Associated Vasculitis’

✍ Kallenberg, Cees G.M.; Stegeman, Coen A.; Abdulahad, Wayel H.; Heeringa, Peter 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 109 KB

Rituximab beneficial in ANCA-associated

Rituximab beneficial in ANCA-associated vasculitis

📂 Article 📅 2007 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Regulatory B cells in ANCA-associated va

Regulatory B cells in ANCA-associated vasculitis

✍ Wilde, B.; Thewissen, M.; Damoiseaux, J.; Knippenberg, S.; Hilhorst, M.; van Paa 📂 Article 📅 2013 🏛 BMJ Publishing Group 🌐 English ⚖ 227 KB

Rituximab in ANCA-Associated Vasculitis:

Rituximab in ANCA-Associated Vasculitis: Fad or Fact?

✍ Fervenza, Fernando C. 📂 Article 📅 2011 🏛 S. Karger AG 🌐 English ⚖ 199 KB

Rituximab versus Cyclophosphamide in ANC

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

✍ Jones, Rachel B.; Cohen Tervaert, Jan Willem; Hauser, Thomas; Luqmani, Raashid; 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 408 KB

Rituximab versus Cyclophosphamide in ANC

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

✍ Jones, Rachel B.; Cohen Tervaert, Jan Willem; Hauser, Thomas; Luqmani, Raashid; 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 408 KB

## Background: Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (anca)-associated vasculitis are effective in 70 to 90% of patients, but they are associated with high rates of death and adverse events. treatment with rituximab has led to remission rates of 80 to 90% among